Business Context and Reporting Period
This Form 8-K Current Report was filed by Achieve Life Sciences, Inc. on March 8, 2022. The report discloses corporate governance changes effective March 14, 2022, specifically the appointment of a new director to the Board.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and associated compensation arrangements.
Material Changes
The primary material change reported is the appointment of Vaughn Himes, PhD., as a director of the Company. No financial performance changes or operational shifts are detailed in this document.
Management Commentary and Compensation Details
In connection with Dr. Himes' appointment, the following compensatory arrangements were established:
- Cash Retainer: An annual cash retainer of $40,000 for Board service.
- Equity Grant: An initial stock option grant to purchase up to 6,600 shares of common stock.
- Exercise Price: Equal to the closing stock price on the Nasdaq Stock Market on the grant date.
- Vesting Schedule: Options vest monthly over 36 months, commencing one month from the grant date.
- Committee Assignment: Dr. Himes has not been appointed to a committee of the Board at this time.
The Company confirmed there are no family relationships between Dr. Himes and existing directors or officers, and no undisclosed material interests in transactions.
Investor Verification Checklist
- Verify the closing stock price on the grant date to determine the exercise price of the 6,600 options.
- Review the Company's 2018 Equity Incentive Plan for specific terms regarding option grants.
- Monitor future filings for Dr. Himes' potential assignment to Board committees.
- Confirm the total number of outstanding options under the 2018 Plan to assess dilution impact.